Exploring the role of IL-32 as a potential biomarker and therapeutic target in premature cardio-vascular diseases during HIV-infection

Active Project Grant Awarded Last action

Award ID
R01AG054324
Recipient
Awarding agency
Obligated
$6,813,565

Award facts

Assistance listing
93.866 Aging Research
Completion date 95% complete
Originally
Place of performance
2323 Riverside Dr., Ottawa, ON K1H 1A1, Canada

Award details come from USAspending.gov.

Transactions

Action Obligated Date
Amendment $0
Amendment $829,283
Amendment $829,283
Amendment $427,996
Amendment $433,719
Amendment Role of IL-32 as a predictor and mediator of premature aging phenotypes(PAP) in HIV infection. $433,719
Amendment $0
Amendment $0
Amendment $0
Amendment $439,372
Amendment $439,372
Amendment $439,372
Amendment Role of IL-32 as a predictor and mediator of premature aging phenotypes(PAP) in HIV infection. $439,372
Amendment $438,200
Amendment $399,411
Amendment $434,974
Amendment $395,625
Original award $433,867
Show all 18

Quick answers

Who received award R01AG054324?

R01AG054324 was awarded to Sante Quebec Centre Hospitalier De L'universite De Montreal by National Institute on Aging (National Institutes of Health) on September 30, 2016.

How much is award R01AG054324 worth?

$6,813,565 has been obligated on R01AG054324.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award